OBJECTIVES: To examine whether the frequency of fusion-negative alveolar rhabdomyosarcoma (ARMSn) increased coincident with changes in the definition of alveolar histology. METHODS: We re-reviewed alveolar rhabdomyosarcoma (ARMS) in the Children's Oncology Group study D9803, comparing histopathology with fusion status. RESULTS: Our review of 255 original ARMS cases (compared with a control group of 38 embryonal rhabdomyosarcomas [ERMS] cases) revealed that many had an ARMS-like densely cellular pattern with cytologic features and myogenin expression more typical of ERMS. Following re-review, 84 (33%) cases of original ARMS were rediagnosed as ERMS. All reclassified ERMS, including dense ERMS, were fusion negative, whereas 82% of confirmed ARMS cases were fusion positive. Total ARMS diagnoses returned to historic rates of 25% to 30% of all rhabdomyosarcomas, and ARMSn decreased from 37% to 18% of ARMS cases. The outcome of reclassified ERMS was similar to confirmed ERMS. CONCLUSIONS: To address the role of fusion status in risk stratification, pathologists should include both a histologic diagnosis and an evaluation of fusion status for all new ARMS diagnoses.
OBJECTIVES: To examine whether the frequency of fusion-negative alveolar rhabdomyosarcoma (ARMSn) increased coincident with changes in the definition of alveolar histology. METHODS: We re-reviewed alveolar rhabdomyosarcoma (ARMS) in the Children's Oncology Group study D9803, comparing histopathology with fusion status. RESULTS: Our review of 255 original ARMS cases (compared with a control group of 38 embryonal rhabdomyosarcomas [ERMS] cases) revealed that many had an ARMS-like densely cellular pattern with cytologic features and myogenin expression more typical of ERMS. Following re-review, 84 (33%) cases of original ARMS were rediagnosed as ERMS. All reclassified ERMS, including dense ERMS, were fusion negative, whereas 82% of confirmed ARMS cases were fusion positive. Total ARMS diagnoses returned to historic rates of 25% to 30% of all rhabdomyosarcomas, and ARMSn decreased from 37% to 18% of ARMS cases. The outcome of reclassified ERMS was similar to confirmed ERMS. CONCLUSIONS: To address the role of fusion status in risk stratification, pathologists should include both a histologic diagnosis and an evaluation of fusion status for all new ARMS diagnoses.
Authors: Frederic G Barr; Stephen J Qualman; Michele H Macris; Natalya Melnyk; Elizabeth R Lawlor; Donna M Strzelecki; Timothy J Triche; Julia A Bridge; Poul H B Sorensen Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701
Authors: P Dias; B Chen; B Dilday; H Palmer; H Hosoi; S Singh; C Wu; X Li; J Thompson; D Parham; S Qualman; P Houghton Journal: Am J Pathol Date: 2000-02 Impact factor: 4.307
Authors: Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2013-03-22 Impact factor: 3.167
Authors: W A Newton; E A Gehan; B L Webber; H B Marsden; A J van Unnik; A B Hamoudi; M G Tsokos; H Shimada; D Harms; D Schmidt Journal: Cancer Date: 1995-09-15 Impact factor: 6.860
Authors: I Leuschner; W A Newton; D Schmidt; N Sachs; L Asmar; A Hamoudi; D Harms; H M Maurer Journal: Am J Surg Pathol Date: 1993-03 Impact factor: 6.394
Authors: M Tsokos; B L Webber; D M Parham; R A Wesley; A Miser; J S Miser; E Etcubanas; T Kinsella; J Grayson; E Glatstein Journal: Arch Pathol Lab Med Date: 1992-08 Impact factor: 5.534
Authors: Michael A Arnold; James R Anderson; Julie M Gastier-Foster; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; R Beverly Raney; David M Parham; Lisa A Teot; Erin R Rudzinski; David O Walterhouse Journal: Pediatr Blood Cancer Date: 2016-01-12 Impact factor: 3.167
Authors: Douglas S Hawkins; Yueh-Yun Chi; James R Anderson; Jing Tian; Carola A S Arndt; Lisa Bomgaars; Sarah S Donaldson; Andrea Hayes-Jordan; Leo Mascarenhas; Mary Beth McCarville; Jeannine S McCune; Geoff McCowage; Lynn Million; Carol D Morris; David M Parham; David A Rodeberg; Erin R Rudzinski; Margarett Shnorhavorian; Sheri L Spunt; Stephen X Skapek; Lisa A Teot; Suzanne Wolden; Torunn I Yock; William H Meyer Journal: J Clin Oncol Date: 2018-08-09 Impact factor: 44.544
Authors: Erin R Rudzinski; James R Anderson; Elizabeth R Lyden; Julia A Bridge; Frederic G Barr; Julie M Gastier-Foster; Karen Bachmeyer; Stephen X Skapek; Douglas S Hawkins; Lisa A Teot; David M Parham Journal: Am J Surg Pathol Date: 2014-05 Impact factor: 6.394
Authors: Atif A Ahmed; Sultan S Habeebu; Ashley K Sherman; Shui Q Ye; Nicole Wood; Katherine M Chastain; Maria G Tsokos Journal: J Histochem Cytochem Date: 2018-03-29 Impact factor: 2.479
Authors: Erin R Rudzinski; James R Anderson; Yueh-Yun Chi; Julie M Gastier-Foster; Caroline Astbury; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; Brenda J Weigel; Alberto Pappo; William H Meyer; Michael A Arnold; Lisa A Teot; David M Parham Journal: Pediatr Blood Cancer Date: 2017-05-18 Impact factor: 3.167
Authors: David O Walterhouse; Donald A Barkauskas; David Hall; Andrea Ferrari; Gian Luca De Salvo; Ewa Koscielniak; Michael C G Stevens; Hélène Martelli; Guido Seitz; David A Rodeberg; Margarett Shnorhavorian; Roshni Dasgupta; John C Breneman; James R Anderson; Christophe Bergeron; Gianni Bisogno; William H Meyer; Douglas S Hawkins; Veronique Minard-Colin Journal: J Clin Oncol Date: 2018-10-23 Impact factor: 44.544
Authors: Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins Journal: Eur J Cancer Date: 2013-12-18 Impact factor: 9.162